PDCD1 and melanoma: In addition, the combination of PD-1 inhibitor and denosumab that inhibits receptor activator of nuclear factor kappa-B ligand (RANKL), which promotes osteoclast formation and has an immunological effect, showed good therapeutic signals in patients with bone metastasis from melanoma (116).